Rx&D applauds Health Canada for progress in Canadian policy on drugs for rare diseases

OTTAWA, Oct. 3, 2012 /CNW/ - Canada's Research-Based Pharmaceutical Companies (Rx&D) welcome Health Canada's announcement that it is developing a regulatory framework surrounding medicines for rare diseases.

"Health Canada's commitment to develop a regulatory framework for rare diseases is critical to improving the health and quality of life for hundreds of thousands of Canadians," said Russell Williams, President of Rx&D.

During consultations undertaken by Health Canada, Rx&D advocated for regulations specific to medicines for rare diseases, with the goal of increasing the research, development and availability of new treatments. A framework aligned with other jurisdictions such as the United States and Europe will lay the foundation for a more efficient and global approach, and ultimately more timely access to the best medicines.

"The framework announced today aims to spur information-sharing and new discovery, and is a great start. But new treatments can only be effective if they are available to the people who need them.  We encourage the government to also work quickly to improve access to these life-saving medications," added Mr. Williams. "We look forward to continued collaboration with Canadians living with rare diseases, healthcare professionals and Health Canada to create the best environment to promote new science and realize better health outcomes for as many Canadians as possible."

Approximately 1 in 12 Canadians is living with a rare disease. A rare disease is a life-threatening, seriously debilitating, or serious condition affecting a small number of patients.

About Rx&D

Rx&D is the association of leading research-based pharmaceutical companies dedicated to improving the health of Canadians through the discovery and development of new medicines and vaccines. Our community invests more than $1 billion in research and development each year to fuel Canada's knowledge-based economy. Guided by our Code of Ethical Practices, our membership is committed to working in partnership with governments, healthcare professionals and stakeholders in a highly ethical manner.

SOURCE: CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX&D)